Dyne Therapeutics prices $375M public offering of 18.3M shares at $20.50

Filed July 22, 2026 · Period ending July 21, 2026 · ~1 min read

Key Changes

• high

  Priced underwritten offering of 18.3M shares at $20.50/share for gross proceeds of $375.1M (18.3M × $20.50), with underwriters purchasing at $19.27/share ($1.23 discount). Expected to close July 23, 2026.

  Item 1.01 verify on EDGAR →
• high

  Net proceeds of ~$352M (or ~$405M if 2.745M-share greenshoe fully exercised), combined with existing cash and June 2026 $50M Hercules term loan, extend cash runway into Q2 2028.

  Item 8.01 verify on EDGAR →
• medium

  Granted underwriters 30-day option to purchase up to 2.745M additional shares at same net price, representing 15% over-allotment provision.

  Item 1.01 verify on EDGAR →